|
OligoMedicines
Located in Milford, Massachusetts, Avecia Biotechnology Inc. is a
recognized leader in therapeutic nucleic acid manufacturing and
development services. Avecia provides services for DNA and RNA
based therapeutics to customers from pre-clinical through
commercial launch. In addition to cGMP (current Good
Manufacturing Practices) manufacturing, Avecia's services include
the development of analytical methods, process validation, stability
studies, quality control, and regulatory support.
Effective 2nd February 2011, Japan's leading diversified materials
manufacturer, Nitto Denko Corporation, has acquired Avecia
Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned
subsidiary in Teaneck, New Jersey. Nitto Denko aims to strengthen
its business base in the domain of nucleic acid drugs with this
acquisition, in light of the industry's great growth potential. Click here to read the press release.
Biologics
Effective 1st Feb 2010, MSD (operating in the US and Canada as
Merck & Co,. Inc.) acquired Avecia Biologics Limited and all its assets. For further
information on this business go to www.biomanufacturingnetwork.com
|

|